Literature DB >> 19033662

The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.

Zhen Lu1, Robert Z Luo, Yiling Lu, Xuhui Zhang, Qinghua Yu, Shilpi Khare, Seiji Kondo, Yasuko Kondo, Yinhua Yu, Gordon B Mills, Warren S-L Liao, Robert C Bast.   

Abstract

The role of autophagy in oncogenesis remains ambiguous, and mechanisms that induce autophagy and regulate its outcome in human cancers are poorly understood. The maternally imprinted Ras-related tumor suppressor gene aplasia Ras homolog member I (ARHI; also known as DIRAS3) is downregulated in more than 60% of ovarian cancers, and here we show that re-expression of ARHI in multiple human ovarian cancer cell lines induces autophagy by blocking PI3K signaling and inhibiting mammalian target of rapamycin (mTOR), upregulating ATG4, and colocalizing with cleaved microtubule-associated protein light chain 3 (LC3) in autophagosomes. Furthermore, ARHI is required for spontaneous and rapamycin-induced autophagy in normal and malignant cells. Although ARHI re-expression led to autophagic cell death when SKOv3 ovarian cancer cells were grown in culture, it enabled the cells to remain dormant when they were grown in mice as xenografts. When ARHI levels were reduced in dormant cells, xenografts grew rapidly. However, inhibition of ARHI-induced autophagy with chloroquine dramatically reduced regrowth of xenografted tumors upon reduction of ARHI levels, suggesting that autophagy contributed to the survival of dormant cells. Further analysis revealed that autophagic cell death was reduced when cultured human ovarian cancer cells in which ARHI had been re-expressed were treated with growth factors (IGF-1, M-CSF), angiogenic factors (VEGF, IL-8), and matrix proteins found in xenografts. Thus, ARHI can induce autophagic cell death, but can also promote tumor dormancy in the presence of factors that promote survival in the cancer microenvironment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19033662      PMCID: PMC2582930          DOI: 10.1172/JCI35512

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis.

Authors:  Katsuhiko Asanuma; Isei Tanida; Isao Shirato; Takashi Ueno; Hisatsugu Takahara; Tomohito Nishitani; Eiki Kominami; Yasuhiko Tomino
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

Review 2.  Defective autophagy leads to cancer.

Authors:  Aimee L Edinger; Craig B Thompson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

Review 3.  Autophagy: molecular mechanisms, physiological functions and relevance in human pathology.

Authors:  G Mariño; C López-Otín
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

4.  Ras is involved in the negative control of autophagy through the class I PI3-kinase.

Authors:  Shuichi Furuta; Eiko Hidaka; Aya Ogata; Sadaki Yokota; Tohru Kamata
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

5.  The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.

Authors:  S Arico; A Petiot; C Bauvy; P F Dubbelhuis; A J Meijer; P Codogno; E Ogier-Denis
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

6.  Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.

Authors:  Lin Wang; Ashraful Hoque; Robert Z Luo; Jiuhong Yuan; Zhen Lu; Arata Nishimoto; Jinsong Liu; Aysegul A Sahin; Scott M Lippman; Robert C Bast; Yinhua Yu
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

7.  Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.

Authors:  Yong Li; Ken Inoki; Kun-Liang Guan
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

8.  Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene.

Authors:  Xueping Qu; Jie Yu; Govind Bhagat; Norihiko Furuya; Hanina Hibshoosh; Andrea Troxel; Jeffrey Rosen; Eeva-Liisa Eskelinen; Noboru Mizushima; Yoshinori Ohsumi; Giorgio Cattoretti; Beth Levine
Journal:  J Clin Invest       Date:  2003-11-24       Impact factor: 14.808

9.  Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.

Authors:  Jia-Ju Bao; Xiao-Feng Le; Rui-Yu Wang; Jiuhong Yuan; Lin Wang; Edward N Atkinson; Ruth LaPushin; Michael Andreeff; Bingliang Fang; Yinhua Yu; Robert C Bast
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

Review 10.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

View more
  195 in total

1.  ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.

Authors:  Hua Li; Benjamin G Bitler; Vinod Vathipadiekal; Marie E Maradeo; Michael Slifker; Caretha L Creasy; Peter J Tummino; Paul Cairns; Michael J Birrer; Rugang Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-05

Review 2.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

3.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

Review 4.  Autophagy inhibitors.

Authors:  Benoit Pasquier
Journal:  Cell Mol Life Sci       Date:  2015-12-11       Impact factor: 9.261

5.  TBK1 regulates prostate cancer dormancy through mTOR inhibition.

Authors:  Jin Koo Kim; Younghun Jung; Jingcheng Wang; Jeena Joseph; Anjali Mishra; Elliott E Hill; Paul H Krebsbach; Kenneth J Pienta; Yusuke Shiozawa; Russell S Taichman
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

6.  Mitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein.

Authors:  Gábor Egervári; Agnes Márk; Melinda Hajdu; Gábor Barna; Zoltán Sápi; Tibor Krenács; László Kopper; Anna Sebestyén
Journal:  Histochem Cell Biol       Date:  2011-03-20       Impact factor: 4.304

7.  Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence.

Authors:  David D Tran; Callie Ann S Corsa; Hirak Biswas; Rebecca L Aft; Gregory D Longmore
Journal:  Mol Cancer Res       Date:  2011-10-17       Impact factor: 5.852

8.  Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.

Authors:  Min-Yu Chen; Warren S-L Liao; Zhen Lu; William G Bornmann; Violeta Hennessey; Michele N Washington; Gary L Rosner; Yinhua Yu; Ahmed Ashour Ahmed; Robert C Bast
Journal:  Cancer       Date:  2011-10-01       Impact factor: 6.860

Review 9.  Life history trade-offs in cancer evolution.

Authors:  C Athena Aktipis; Amy M Boddy; Robert A Gatenby; Joel S Brown; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2013-11-11       Impact factor: 60.716

Review 10.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.